Warburg Pincus is on the brink of a $7 billion purchase of specialty‑pharmacy firm Panthe Rx Rare, including debt, according to insiders. The deal would value the company at roughly $6.5 billion in equity, a premium over its current market cap.

Panthe Rx Rare sits in an investor consortium that includes General Atlantic. Warburg is partnering with the sovereign‑wealth fund ADIA, giving the transaction a cross‑border flavor that could shorten the closing window.

A transaction of this scale signals robust investor appetite for high‑margin, contract‑based pharmacies, a segment that has grown faster than the broader pharmacy market. The deal could lift valuations across the specialty‑pharmacy niche and pressure competitors to seek similar backing.

For Warburg, the acquisition expands its U.S. footprint and offers access to a network of pharmacies that can drive cost efficiencies. ADIA gains exposure to a U.S. industry projected to exceed $150 billion in 2025. Investors will focus on regulatory approvals and integration costs, which will shape the net value of the transaction.